Conduit Research Development vs Ebitda Analysis

CDTTW Stock

0.01 0.0002 1.83%

Conduit Pharmaceuticals financial indicator trend analysis is way more than just evaluating Conduit Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Conduit Pharmaceuticals is a good investment. Please check the relationship between Conduit Pharmaceuticals Research Development and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Conduit Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Research Development vs Ebitda

Research Development vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Conduit Pharmaceuticals Research Development account and Ebitda. At this time, the significance of the direction appears to have strong relationship.

The correlation between Conduit Pharmaceuticals' Research Development and Ebitda is 0.76. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Ebitda in the same time period over historical financial statements of Conduit Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Conduit Pharmaceuticals' Research Development and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Conduit Pharmaceuticals are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Research Development i.e., Conduit Pharmaceuticals' Research Development and Ebitda go up and down completely randomly.

Correlation Coefficient

0.76

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Research Development

Ebitda

Most indicators from Conduit Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Conduit Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Conduit Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.Selling General Administrative is likely to drop to about 4.1 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

Conduit Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Short Term Debt	Common Stock	Other Assets	Short Long Term Debt	Net Working Capital	Intangible Assets
Total Assets		0.32	-0.9	-0.31	0.9	-0.99	-0.82	1.0	1.0	0.14	0.7	1.0	0.9	0.73	0.99	0.23	0.52	0.95	1.0	1.0	-0.13	0.95	0.95	1.0	-0.95
Short Long Term Debt Total	0.32		0.12	0.8	-0.13	-0.16	-0.8	0.38	0.29	-0.87	0.76	0.38	0.22	0.86	0.45	-0.83	0.97	0.01	0.4	0.34	0.88	0.26	0.26	0.34	-0.38
Other Current Liab	-0.9	0.12		0.69	-1.0	0.96	0.49	-0.87	-0.92	-0.55	-0.36	-0.87	-0.81	-0.36	-0.83	-0.63	-0.1	-0.99	-0.86	-0.89	0.54	-0.85	-0.85	-0.89	0.84
Total Current Liabilities	-0.31	0.8	0.69		-0.7	0.46	-0.29	-0.24	-0.34	-0.97	0.34	-0.24	-0.32	0.41	-0.17	-0.99	0.65	-0.59	-0.23	-0.29	0.97	-0.32	-0.32	-0.29	0.23
Total Stockholder Equity	0.9	-0.13	-1.0	-0.7		-0.95	-0.48	0.86	0.91	0.56	0.36	0.86	0.81	0.35	0.82	0.64	0.09	0.99	0.85	0.89	-0.55	0.85	0.85	0.89	-0.83
Net Debt	-0.99	-0.16	0.96	0.46	-0.95		0.72	-0.97	-0.99	-0.29	-0.61	-0.97	-0.9	-0.61	-0.95	-0.38	-0.37	-0.99	-0.97	-0.98	0.28	-0.95	-0.95	-0.98	0.92
Retained Earnings	-0.82	-0.8	0.49	-0.29	-0.48	0.72		-0.86	-0.8	0.45	-0.94	-0.86	-0.73	-0.99	-0.89	0.37	-0.91	-0.6	-0.87	-0.83	-0.47	-0.78	-0.78	-0.83	0.8
Cash	1.0	0.38	-0.87	-0.24	0.86	-0.97	-0.86		0.99	0.07	0.75	1.0	0.9	0.77	1.0	0.16	0.58	0.92	1.0	1.0	-0.05	0.95	0.95	1.0	-0.95
Non Current Assets Total	1.0	0.29	-0.92	-0.34	0.91	-0.99	-0.8	0.99		0.17	0.68	0.99	0.9	0.7	0.98	0.26	0.49	0.96	0.99	1.0	-0.16	0.94	0.95	1.0	-0.95
Non Currrent Assets Other	0.14	-0.87	-0.55	-0.97	0.56	-0.29	0.45	0.07	0.17		-0.53	0.07	0.11	-0.58	0.0	1.0	-0.76	0.44	0.05	0.12	-1.0	0.11	0.11	0.12	-0.11
Long Term Debt	0.7	0.76	-0.36	0.34	0.36	-0.61	-0.94	0.75	0.68	-0.53		0.75	0.78	0.96	0.79	-0.46	0.86	0.48	0.76	0.71	0.55	0.78	0.78	0.72	-0.59
Cash And Short Term Investments	1.0	0.38	-0.87	-0.24	0.86	-0.97	-0.86	1.0	0.99	0.07	0.75		0.9	0.77	1.0	0.16	0.58	0.92	1.0	1.0	-0.05	0.95	0.95	1.0	-0.95
Common Stock Shares Outstanding	0.9	0.22	-0.81	-0.32	0.81	-0.9	-0.73	0.9	0.9	0.11	0.78	0.9		0.68	0.89	0.19	0.42	0.86	0.9	0.89	-0.1	0.99	0.99	0.9	-0.71
Non Current Liabilities Total	0.73	0.86	-0.36	0.41	0.35	-0.61	-0.99	0.77	0.7	-0.58	0.96	0.77	0.68		0.82	-0.5	0.95	0.48	0.78	0.74	0.59	0.72	0.72	0.74	-0.69
Other Current Assets	0.99	0.45	-0.83	-0.17	0.82	-0.95	-0.89	1.0	0.98	0.0	0.79	1.0	0.89	0.82		0.09	0.63	0.9	1.0	0.99	0.02	0.94	0.94	0.99	-0.94
Other Stockholder Equity	0.23	-0.83	-0.63	-0.99	0.64	-0.38	0.37	0.16	0.26	1.0	-0.46	0.16	0.19	-0.5	0.09		-0.7	0.52	0.14	0.21	-0.99	0.2	0.2	0.21	-0.2
Total Liab	0.52	0.97	-0.1	0.65	0.09	-0.37	-0.91	0.58	0.49	-0.76	0.86	0.58	0.42	0.95	0.63	-0.7		0.22	0.59	0.53	0.77	0.46	0.47	0.53	-0.55
Net Invested Capital	0.95	0.01	-0.99	-0.59	0.99	-0.99	-0.6	0.92	0.96	0.44	0.48	0.92	0.86	0.48	0.9	0.52	0.22		0.92	0.94	-0.43	0.9	0.9	0.94	-0.89
Total Current Assets	1.0	0.4	-0.86	-0.23	0.85	-0.97	-0.87	1.0	0.99	0.05	0.76	1.0	0.9	0.78	1.0	0.14	0.59	0.92		1.0	-0.04	0.94	0.95	1.0	-0.95
Short Term Debt	1.0	0.34	-0.89	-0.29	0.89	-0.98	-0.83	1.0	1.0	0.12	0.71	1.0	0.89	0.74	0.99	0.21	0.53	0.94	1.0		-0.11	0.94	0.95	1.0	-0.95
Common Stock	-0.13	0.88	0.54	0.97	-0.55	0.28	-0.47	-0.05	-0.16	-1.0	0.55	-0.05	-0.1	0.59	0.02	-0.99	0.77	-0.43	-0.04	-0.11		-0.1	-0.1	-0.1	0.1
Other Assets	0.95	0.26	-0.85	-0.32	0.85	-0.95	-0.78	0.95	0.94	0.11	0.78	0.95	0.99	0.72	0.94	0.2	0.46	0.9	0.94	0.94	-0.1		1.0	0.95	-0.8
Short Long Term Debt	0.95	0.26	-0.85	-0.32	0.85	-0.95	-0.78	0.95	0.95	0.11	0.78	0.95	0.99	0.72	0.94	0.2	0.47	0.9	0.95	0.95	-0.1	1.0		0.96	-0.81
Net Working Capital	1.0	0.34	-0.89	-0.29	0.89	-0.98	-0.83	1.0	1.0	0.12	0.72	1.0	0.9	0.74	0.99	0.21	0.53	0.94	1.0	1.0	-0.1	0.95	0.96		-0.95
Intangible Assets	-0.95	-0.38	0.84	0.23	-0.83	0.92	0.8	-0.95	-0.95	-0.11	-0.59	-0.95	-0.71	-0.69	-0.94	-0.2	-0.55	-0.89	-0.95	-0.95	0.1	-0.8	-0.81	-0.95

Click cells to compare fundamentals

Conduit Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Conduit Research Development vs Ebitda Analysis

Research Development vs Ebitda

Research Development vs Ebitda Correlation Analysis

Correlation Coefficient

Research Development

Ebitda

Conduit Pharmaceuticals fundamental ratios Correlations

Conduit Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Conduit Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Short Term Debt	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets

Common Stock	- 1.0	Non Currrent Assets Other
Total Stockholder Equity	- 1.0	Other Current Liab
Common Stock	- 0.99	Other Stockholder Equity
Non Current Liabilities Total	- 0.99	Retained Earnings
Net Invested Capital	- 0.99	Net Debt
Non Current Assets Total	- 0.99	Net Debt